Video

Molecular Testing and Actionable Targets in NSCLC

For High-Definition, Click

In this segment, Mark A. Socinski, MD, addresses the topic of which molecular tests should be administered. In terms of actionable targets EGFR and EML4-ALK are the most important mutations to test for in day-to-day practice, since guidelines dictate a standard of care for patients with these mutations. At this point, testing for KRAS, ROS1, and BRAF may only be actionable within the confines of a clinical trial.

There is some discrepancy as to whether testing for multiple mutations should be conducted concurrently or sequentially. Corey J. Langer, MD, notes that as tissue depletes and patients are ill it may be best to use tissue efficiently by screening for the most common and actionable aberrations first, which are EGFR and EML4-ALK. Socinski notes that although ROS1 or other mutations may be rare, when they are found it makes a big difference.

In the future, the panel agrees, oncologists may have to test for ROS1, BRAF, and KRAS, as those mutations may have actionable targets in the near future.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity